Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AVITA Medical Inc RCEL

Healthcare Biotechnology
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile... see more

Recent & Breaking News (NDAQ:RCEL)

AVITA Medical to Present at Upcoming Investor Conferences

GlobeNewswire November 16, 2021

AVITA Medical Reports First Fiscal Quarter 2022 Financial Results

GlobeNewswire November 8, 2021

AVITA Medical Announces Expanded Medicare Reimbursement to Outpatient Hospital and Ambulatory Surgical Centers

GlobeNewswire November 3, 2021

Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn Surgeons

GlobeNewswire October 28, 2021

AVITA Medical to Announce Fiscal First Quarter 2022 Financial Results

GlobeNewswire October 25, 2021

AVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare Conference

GlobeNewswire September 13, 2021

AVITA Medical to Participate at the Lake Street 2021 BIG5 Conference

GlobeNewswire August 31, 2021

AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results

GlobeNewswire August 26, 2021

FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical's Pivotal Study of the RECELL® System for Vitiligo Treatment

GlobeNewswire August 16, 2021

AVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results

GlobeNewswire August 12, 2021

AVITA Medical Announces Inclusion in the Russell 3000 Index

GlobeNewswire June 29, 2021

AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results

GlobeNewswire June 15, 2021

U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients

GlobeNewswire June 10, 2021

AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

GlobeNewswire June 1, 2021

AVITA Medical Reports Third Quarter 2021 Financial Results

GlobeNewswire May 13, 2021

AVITA Medical to Announce Fiscal Third Quarter 2021 Financial Results

GlobeNewswire April 29, 2021

15 RECELL® System Abstracts Accepted for Presentation at 53?? Annual American Burn Association Meeting

GlobeNewswire March 30, 2021

AVITA Medical, Inc. Names Michael Holder as Chief Financial Officer

GlobeNewswire March 22, 2021

Avita Medical, Inc. Announces Closing of Offering of 3,214,250 Shares of Common Stock

GlobeNewswire March 1, 2021

AVITA Medical, Inc. Announces Pricing of Its Public Offering of Common Stock

GlobeNewswire February 25, 2021